RT Journal Article
SR Electronic
T1 Researching COVID to enhance recovery (RECOVER) autopsy tissue pathology study protocol: Rationale, objectives, and design
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.27.23289234
DO 10.1101/2023.04.27.23289234
A1 Troxel, Andrea B.
A1 Bind, Marie-Abele C.
A1 Flotte, Thomas J.
A1 Cordon-Cardo, Carlos
A1 Decker, Lauren A.
A1 Finn, Aloke V.
A1 Padera, Robert F.
A1 Reichard, R. Ross
A1 Stone, James R.
A1 Adolphi, Natalie L.
A1 Casimero, Faye Victoria C.
A1 Crary, John F.
A1 Elifritz, Jamie
A1 Faustin, Arline
A1 Ghosh, Saikat Kumar B.
A1 Krausert, Amanda
A1 Martinez-Lage, Maria
A1 Melamed, Jonathan
A1 Mitchell, Roger A.
A1 Sampson, Barbara A.
A1 Seifert, Alan C.
A1 Simsir, Aylin
A1 Adams, Cheryle
A1 Haasnoot, Stephanie
A1 Hafner, Stephanie
A1 Siciliano, Michelle A.
A1 Vallejos, Brittany B.
A1 Boccio, Phoebe Del
A1 Lamendola-Essel, Michelle F.
A1 Young, Chloe E.
A1 Kewlani, Deepshikha
A1 Akinbo, Precious A.
A1 Parent, Brendan
A1 Chung, Alicia
A1 Cato, Teresa C.
A1 Mudumbi, Praveen C.
A1 Esquenazi-Karonika, Shari
A1 Wood, Marion J.
A1 Chan, James
A1 Monteiro, Jonathan
A1 Shinnick, Daniel J.
A1 Thaweethai, Tanayott
A1 Nguyen, Amber N.
A1 Fitzgerald, Megan L.
A1 Perlowski, Alice A.
A1 Stiles, Lauren E.
A1 Paskett, Moira L.
A1 Katz, Stuart D.
A1 Foulkes, Andrea S.
YR 2023
UL http://medrxiv.org/content/early/2023/05/04/2023.04.27.23289234.abstract
AB Importance SARS-CoV-2 infection can result in ongoing, relapsing, or new symptoms or organ dysfunction after the acute phase of infection, termed Post-Acute Sequelae of SARS-CoV-2 (PASC), or long COVID. The characteristics, prevalence, trajectory and mechanisms of PASC are poorly understood. The objectives of the Researching COVID to Enhance Recovery (RECOVER) Tissue Pathology Study (RECOVER-Pathology) are to: (1) characterize prevalence and types of organ injury/disease and pathology occurring with PASC; (2) characterize the association of pathologic findings with clinical and other characteristics; (3) define the pathophysiology and mechanisms of PASC, and possible mediation via viral persistence; and (4) establish a post-mortem tissue biobank and post-mortem brain imaging biorepository.Methods RECOVER-Pathology is a cross-sectional study of decedents dying at least 15 days following initial SARS-CoV-2 infection. Eligible decedents must meet WHO criteria for suspected, probable, or confirmed infection and must be aged 18 years or more at the time of death. Enrollment occurs at 7 sites in four U.S. states and Washington, DC. Comprehensive autopsies are conducted according to a standardized protocol within 24 hours of death; tissue samples are sent to the PASC Biorepository for later analyses. Data on clinical history are collected from the medical records and/or next of kin. The primary study outcomes include an array of pathologic features organized by organ system. Casual inference methods will be employed to investigate associations between risk factors and pathologic outcomes.Discussion RECOVER-Pathology is the largest autopsy study addressing PASC among US adults. Results of this study are intended to elucidate mechanisms of organ injury and disease and enhance our understanding of the pathophysiology of PASC.Clinicaltrials.gov number: NCT05292274Competing Interest StatementI have read the journal's policy and the authors of this manuscript have the following competing interests: Brendan Parent reports receiving a research gift from United Therapeutics.Clinical TrialClinical Trial Registration: Unique identifier: NCT05292274? http://www.clinicaltrials.gov.Clinical Protocols https://recovercovid.org/sites/default/files/docs/Autopsy.Protocol.v2.0.pdf Funding StatementNational Institutes of Health (NIH) Agreement OTA OT2HL161841 (ASF), OT2HL156812 (N/A), OT2HL161847-01 (SDK/ABT) https://www.nih.gov/ The funders did not and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB: NYU Grossman School of MedicineI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Not ApplicableNo datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion.